Arrowstreet Capital, Limited Partnership Spero Therapeutics, Inc. Transaction History
Arrowstreet Capital, Limited Partnership
- $122 Billion
- Q4 2024
Shares
3 transactions
Others Institutions Holding SPRO
# of Institutions
53Shares Held
14.9MCall Options Held
200Put Options Held
200-
Anson Funds Management LP Dallas, TX3.84MShares$3.19 Million0.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.76MShares$1.46 Million0.0% of portfolio
-
Atlas Venture Associates Ix, LLC Boston, MA1.35MShares$1.12 Million14.54% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.11MShares$917,6400.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.04MShares$863,1350.0% of portfolio
About Spero Therapeutics, Inc.
- Ticker SPRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,067,500
- Market Cap $29.1M
- Description
- Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...